Background We previously reported the initial results of the first multicenter, randomized,
double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT),
observing a favorable safety profile associated with modest clinical and immunologic effects
in the first year. Objective We sought to provide long-term (3-year) clinical and immunologic
outcomes for our peanut SLIT trial. Key end points were (1) percentage of responders at 2
years (ie, could consume 5 g of peanut powder or a 10-fold increase from baseline),(2) …